Medroxyprogesterone Dosing for Hypoventilation
For adult patients with hypoventilation, medroxyprogesterone acetate should be dosed at 60 mg per day orally, based on the most robust evidence in this population.
Dosing Regimen
The evidence from multiple studies consistently supports 60 mg/day as the optimal dose for respiratory stimulation in patients with hypoventilation 1:
- Standard dose: 60 mg daily (oral administration)
- Duration: Minimum 14 days to assess response, with treatment typically continued for 3 months 1
- Alternative dosing range: 60-120 mg/day has been studied 1
Evidence Supporting This Recommendation
The 2017 British Journal of Pharmacology guideline review specifically documents that 60 to 120 mg/day was the dosing range used in randomized controlled trials for patients with obstructive sleep apnea and hypoventilation 1. Research studies consistently demonstrate:
- 60 mg/day improved nocturnal oxygenation in postmenopausal women with COPD, increasing mean SaO2 by 1.7% and SaO2 nadir by 3.9%, while decreasing transcutaneous PCO2 by 0.9 kPa 2
- The respiratory improvement persisted for 3 weeks after cessation of therapy 2, 3
- 75 mg/day decreased PaCO2 by approximately 8 mm Hg in hypercapnic COPD patients 4
Comparison with Alternative Dosing
Lower doses used for other indications are inadequate for respiratory stimulation:
- 2.5-5 mg/day (endometrial protection dose) 5 - insufficient for ventilatory effects
- 30 mg twice daily showed benefit in one comparative study but is not the standard 6
- Depot formulations (150 mg IM every 3 months) are designed for contraception, not respiratory stimulation 7, 8
Clinical Considerations
Patient selection matters significantly: The respiratory improvement with medroxyprogesterone was inversely associated with baseline oxygen saturation—patients with lower baseline SaO2 values showed greater improvement 2. This means the medication works best in those with more severe nocturnal hypoxemia.
Mechanism of action: Medroxyprogesterone stimulates central respiratory drive, increasing minute ventilation and tidal volume without significantly changing respiratory rate 4. It improves both hypoxic and hypercapnic ventilatory responses 6.
Duration of effect: The ventilatory improvement is sustained for at least 3 weeks post-treatment 3, and some patients continue to improve even after cessation of therapy 4.
Important Caveats
This is NOT first-line therapy for obstructive sleep apnea. In non-hypercapnic patients with pure obstructive sleep apnea, medroxyprogesterone at 60 mg/day did not significantly reduce apnea frequency or duration 9. The medication is most appropriate for:
- Hypercapnic patients with COPD and nocturnal hypoventilation
- Postmenopausal women with partial upper airway obstruction and hypoventilation
- Patients with obesity hypoventilation syndrome (though evidence is limited)
Contraindications from FDA labeling 10: While the FDA label primarily addresses higher doses (400-1000 mg/week IM) for cancer treatment, clinicians should be aware of standard progestin contraindications including active thromboembolism, breast cancer, and undiagnosed vaginal bleeding.
Fluid retention risk: Monthly injectable medroxyprogesterone acetate (150 mg IM) causes fluid retention and is inappropriate for patients with heart failure 11, 12. While this is less of a concern with the lower oral doses used for respiratory stimulation, monitor patients with cardiovascular disease carefully.
Recent safety signal: A 2025 study found increased meningioma risk with depot medroxyprogesterone acetate, particularly with exposures >4 years 13. While this was with the contraceptive formulation, consider this risk in long-term treatment decisions.